David Domzalski - 31 Mar 2023 Form 4 Insider Report for VYNE Therapeutics Inc. (VYNE)

Role
President and CEO, Director
Signature
/s/ Mutya Harsch, attorney-in-fact for David Domzalski
Issuer symbol
VYNE
Transactions as of
31 Mar 2023
Net transactions value
-$8,421
Form type
4
Filing time
04 Apr 2023, 17:01:23 UTC
Previous filing
04 Jan 2023
Next filing
02 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VYNE Common Stock Tax liability $8,421 -2,734 -5.1% $3.08 50,648 31 Mar 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.
F2 On February 10, 2023, the Issuer effected a one-for-18 reverse split of its Common Stock. The number of securities reported reflects the reverse split.